(BAX) Baxter International - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0718131099
Stock: Medical Devices, Pharmaceuticals, IV
Total Rating 32
Risk 82
Buy Signal -1.78
| Risk 5d forecast | |
|---|---|
| Volatility | 39.3% |
| Relative Tail Risk | -15.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.38 |
| Alpha | -62.86 |
| Character TTM | |
|---|---|
| Beta | 0.481 |
| Beta Downside | -0.310 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.44% |
| CAGR/Max DD | -0.35 |
EPS (Earnings per Share)
Revenue
Description: BAX Baxter International March 05, 2026
Baxter International Inc. is a U.S.-based healthcare company. It operates in three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The company offers a diverse product portfolio, including IV solutions, infusion systems, surgical products, patient monitoring, and injectable pharmaceuticals. These products are utilized across various healthcare settings, from hospitals to home care. The medical device sector is characterized by continuous innovation and stringent regulatory oversight.
Baxter distributes its products through a direct sales force, distributors, wholesalers, and specialty providers. Its global presence spans Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. The pharmaceutical sector often involves significant research and development investments and patent protection.
For more detailed financial analysis, consider exploring ValueRay.
Headlines to watch out for
- Sterile IV solution demand impacts revenue
- Generic injectable pharmaceuticals drive sales
- Healthcare system technology adoption boosts growth
- Regulatory changes affect medical device approvals
- Global supply chain disruptions increase costs
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -957.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.56 > 1.0 |
| NWC/Revenue: 34.70% < 20% (prev 22.02%; Δ 12.68% < -1%) |
| CFO/TA 0.04 > 3% & CFO 845.0m > Net Income -957.0m |
| Net Debt (7.81b) to EBITDA (766.0m): 10.20 < 3 |
| Current Ratio: 2.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (514.0m) vs 12m ago 0.78% < -2% |
| Gross Margin: 30.05% > 18% (prev 0.37%; Δ 2968 % > 0.5%) |
| Asset Turnover: 49.06% > 50% (prev 41.25%; Δ 7.81% > 0%) |
| Interest Coverage Ratio: -0.74 > 6 (EBITDA TTM 766.0m / Interest Expense TTM 290.0m) |
Altman Z'' 4.24
| A: 0.19 (Total Current Assets 6.87b - Total Current Liabilities 2.97b) / Total Assets 20.05b |
| B: 0.68 (Retained Earnings 13.71b / Total Assets 20.05b) |
| C: -0.01 (EBIT TTM -215.0m / Avg Total Assets 22.92b) |
| D: 0.76 (Book Value of Equity 10.63b / Total Liabilities 13.95b) |
| Altman-Z'' Score: 4.24 = AA |
Beneish M -2.85
| DSRI: 1.06 (Receivables 1.93b/1.73b, Revenue 11.24b/10.64b) |
| GMI: 1.25 (GM 30.05% / 37.46%) |
| AQI: 0.93 (AQ_t 0.50 / AQ_t-1 0.53) |
| SGI: 1.06 (Revenue 11.24b / 10.64b) |
| TATA: -0.09 (NI -957.0m - CFO 845.0m) / TA 20.05b) |
| Beneish M-Score: -2.85 (Cap -4..+1) = A |
What is the price of BAX shares?
As of March 11, 2026, the stock is trading at USD 17.46 with a total of 9,353,840 shares traded.
Over the past week, the price has changed by -8.25%, over one month by -20.38%, over three months by -4.33% and over the past year by -51.59%.
Over the past week, the price has changed by -8.25%, over one month by -20.38%, over three months by -4.33% and over the past year by -51.59%.
Is BAX a buy, sell or hold?
Baxter International has received a consensus analysts rating of 3.44.
Therefor, it is recommend to hold BAX.
- StrongBuy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the BAX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.6 | 23.9% |
| Analysts Target Price | 21.6 | 23.9% |
BAX Fundamental Data Overview March 07, 2026
P/E Forward = 9.8619
P/S = 0.8511
P/B = 1.5974
P/EG = 36.6767
Revenue TTM = 11.24b USD
EBIT TTM = -215.0m USD
EBITDA TTM = 766.0m USD
Long Term Debt = 9.47b USD (from longTermDebt, last quarter)
Short Term Debt = 82.0m USD (from shortTermDebt, last quarter)
Debt = 9.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.81b USD (from netDebt column, last quarter)
Enterprise Value = 17.38b USD (9.57b + Debt 9.78b - CCE 1.97b)
Interest Coverage Ratio = -0.74 (Ebit TTM -215.0m / Interest Expense TTM 290.0m)
EV/FCF = 53.82x (Enterprise Value 17.38b / FCF TTM 323.0m)
FCF Yield = 1.86% (FCF TTM 323.0m / Enterprise Value 17.38b)
FCF Margin = 2.87% (FCF TTM 323.0m / Revenue TTM 11.24b)
Net Margin = -8.51% (Net Income TTM -957.0m / Revenue TTM 11.24b)
Gross Margin = 30.05% ((Revenue TTM 11.24b - Cost of Revenue TTM 7.87b) / Revenue TTM)
Gross Margin QoQ = 19.40% (prev 33.51%)
Tobins Q-Ratio = 0.87 (Enterprise Value 17.38b / Total Assets 20.05b)
Interest Expense / Debt = 0.71% (Interest Expense 69.0m / Debt 9.78b)
Taxrate = 21.0% (US default 21%)
NOPAT = -169.8m (EBIT -215.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.31 (Total Current Assets 6.87b / Total Current Liabilities 2.97b)
Debt / Equity = 1.60 (Debt 9.78b / totalStockholderEquity, last quarter 6.13b)
Debt / EBITDA = 10.20 (Net Debt 7.81b / EBITDA 766.0m)
Debt / FCF = 24.19 (Net Debt 7.81b / FCF TTM 323.0m)
Total Stockholder Equity = 6.94b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.18% (Net Income -957.0m / Total Assets 20.05b)
RoE = -13.78% (Net Income TTM -957.0m / Total Stockholder Equity 6.94b)
RoCE = -1.31% (EBIT -215.0m / Capital Employed (Equity 6.94b + L.T.Debt 9.47b))
RoIC = -1.02% (negative operating profit) (NOPAT -169.8m / Invested Capital 16.58b)
WACC = 4.08% (E(9.57b)/V(19.35b) * Re(7.69%) + D(9.78b)/V(19.35b) * Rd(0.71%) * (1-Tc(0.21)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.69%
[DCF] Terminal Value 80.82% ; FCFF base≈417.4m ; Y1≈274.0m ; Y5≈125.0m
[DCF] Fair Price = N/A (negative equity: EV 3.98b - Net Debt 7.81b = -3.83b; debt exceeds intrinsic value)
EPS Correlation: -71.28 | EPS CAGR: -18.09% | SUE: -0.88 | # QB: 0
Revenue Correlation: -69.25 | Revenue CAGR: -5.71% | SUE: 0.10 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.44 | Chg7d=-0.119 | Chg30d=-0.119 | Revisions Net=-9 | Analysts=14
EPS current Year (2026-12-31): EPS=1.92 | Chg7d=+0.001 | Chg30d=-0.350 | Revisions Net=-15 | Growth EPS=-15.5% | Growth Revenue=+1.0%
EPS next Year (2027-12-31): EPS=2.06 | Chg7d=+0.003 | Chg30d=-0.396 | Revisions Net=-10 | Growth EPS=+7.4% | Growth Revenue=+2.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 9 Down within 30d for Next Quarter)
P/S = 0.8511
P/B = 1.5974
P/EG = 36.6767
Revenue TTM = 11.24b USD
EBIT TTM = -215.0m USD
EBITDA TTM = 766.0m USD
Long Term Debt = 9.47b USD (from longTermDebt, last quarter)
Short Term Debt = 82.0m USD (from shortTermDebt, last quarter)
Debt = 9.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.81b USD (from netDebt column, last quarter)
Enterprise Value = 17.38b USD (9.57b + Debt 9.78b - CCE 1.97b)
Interest Coverage Ratio = -0.74 (Ebit TTM -215.0m / Interest Expense TTM 290.0m)
EV/FCF = 53.82x (Enterprise Value 17.38b / FCF TTM 323.0m)
FCF Yield = 1.86% (FCF TTM 323.0m / Enterprise Value 17.38b)
FCF Margin = 2.87% (FCF TTM 323.0m / Revenue TTM 11.24b)
Net Margin = -8.51% (Net Income TTM -957.0m / Revenue TTM 11.24b)
Gross Margin = 30.05% ((Revenue TTM 11.24b - Cost of Revenue TTM 7.87b) / Revenue TTM)
Gross Margin QoQ = 19.40% (prev 33.51%)
Tobins Q-Ratio = 0.87 (Enterprise Value 17.38b / Total Assets 20.05b)
Interest Expense / Debt = 0.71% (Interest Expense 69.0m / Debt 9.78b)
Taxrate = 21.0% (US default 21%)
NOPAT = -169.8m (EBIT -215.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.31 (Total Current Assets 6.87b / Total Current Liabilities 2.97b)
Debt / Equity = 1.60 (Debt 9.78b / totalStockholderEquity, last quarter 6.13b)
Debt / EBITDA = 10.20 (Net Debt 7.81b / EBITDA 766.0m)
Debt / FCF = 24.19 (Net Debt 7.81b / FCF TTM 323.0m)
Total Stockholder Equity = 6.94b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.18% (Net Income -957.0m / Total Assets 20.05b)
RoE = -13.78% (Net Income TTM -957.0m / Total Stockholder Equity 6.94b)
RoCE = -1.31% (EBIT -215.0m / Capital Employed (Equity 6.94b + L.T.Debt 9.47b))
RoIC = -1.02% (negative operating profit) (NOPAT -169.8m / Invested Capital 16.58b)
WACC = 4.08% (E(9.57b)/V(19.35b) * Re(7.69%) + D(9.78b)/V(19.35b) * Rd(0.71%) * (1-Tc(0.21)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.69%
[DCF] Terminal Value 80.82% ; FCFF base≈417.4m ; Y1≈274.0m ; Y5≈125.0m
[DCF] Fair Price = N/A (negative equity: EV 3.98b - Net Debt 7.81b = -3.83b; debt exceeds intrinsic value)
EPS Correlation: -71.28 | EPS CAGR: -18.09% | SUE: -0.88 | # QB: 0
Revenue Correlation: -69.25 | Revenue CAGR: -5.71% | SUE: 0.10 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.44 | Chg7d=-0.119 | Chg30d=-0.119 | Revisions Net=-9 | Analysts=14
EPS current Year (2026-12-31): EPS=1.92 | Chg7d=+0.001 | Chg30d=-0.350 | Revisions Net=-15 | Growth EPS=-15.5% | Growth Revenue=+1.0%
EPS next Year (2027-12-31): EPS=2.06 | Chg7d=+0.003 | Chg30d=-0.396 | Revisions Net=-10 | Growth EPS=+7.4% | Growth Revenue=+2.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 9 Down within 30d for Next Quarter)